Abstract | BACKGROUND: METHODS AND RESULTS: We evaluated 42 mutation-determined heterozygous FH patients with aPCSK9gain-of-function mutation (FH-PCSK9, mean age 52, mean LDL-C 235 mg/dl), 198 mutation-determined heterozygous FH patients with aLDLRmutation (FH-LDLR, mean age 44, mean LDL-C 217 mg/dl), and 4,015 controls (CONTROL, mean age 56, mean LDL-C 109 mg/dl). We assessed their Lp(a), total cholesterol, triglycerides, HDL-C, LDL-C, use of statins, presence of hypertension, diabetes, chronic kidney disease, smoking, body mass index (BMI) and coronary artery disease (CAD). Multiple regression analysis showed that HDL-C, use of statins, presence of hypertension, smoking, BMI, and Lp(a) were independently associated with the presence of CAD. Under these conditions, the serum levels of Lp(a) in patients with FH were significantly higher than those of the CONTROL group regardless of their causative genes, among the groups propensity score-matched (median Lp(a) 12.6 mg/dl [IQR:9.4-33.9], 21.1 mg/dl [IQR:11.7-34.9], and 5.0 mg/dl [IQR:2.7-8.1] in the FH-LDLR, FH-PCSK9, and CONTROL groups, respectively, P=0.002 for FH-LDLR vs. CONTROL, P=0.002 for FH-PCSK9 vs. CONTROL). CONCLUSIONS: These data demonstrate that serum Lp(a) is elevated in patients with FH caused by PCSK9 gain-of-function mutations to the same level as that in FH caused by LDLR mutations.
|
Authors | Hayato Tada, Masa-Aki Kawashiri, Taiji Yoshida, Ryota Teramoto, Atsushi Nohara, Tetsuo Konno, Akihiro Inazu, Hiroshi Mabuchi, Masakazu Yamagishi, Kenshi Hayashi |
Journal | Circulation journal : official journal of the Japanese Circulation Society
(Circ J)
Vol. 80
Issue 2
Pg. 512-8
( 2016)
ISSN: 1347-4820 [Electronic] Japan |
PMID | 26632531
(Publication Type: Clinical Trial, Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- LDLR protein, human
- Lipoprotein(a)
- Receptors, LDL
- PCSK9 protein, human
- Proprotein Convertase 9
- Proprotein Convertases
- Serine Endopeptidases
|
Topics |
- Adult
- Aged
- Female
- Humans
- Hyperlipoproteinemia Type II
(blood, genetics)
- Lipoprotein(a)
(blood)
- Male
- Middle Aged
- Mutation
- Proprotein Convertase 9
- Proprotein Convertases
(genetics, metabolism)
- Receptors, LDL
(genetics, metabolism)
- Retrospective Studies
- Serine Endopeptidases
(genetics, metabolism)
|
|
Join CureHunter, for free Research Interface BASIC access!
Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease.
Find out why thousands of doctors, pharma researchers and patient activists
around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!
|